Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model.
Three clinically relevant intermittent regimens, and a continuous infusion, of colistin were simulated in an in vitro pharmacokinetic/pharmacodynamic model against two colistin-heteroresistant strains of Acinetobacter baumannii. Extensive initial killing was followed by regrowth as early as 6 h later; bacterial density in the 24- to 72-h period was within 1 log(10) CFU/ml of growth control. Population analysis profiles revealed extensive emergence of resistant subpopulations regardless of the colistin regimen.
Tan
Chun-Hong
CH
Facility for Anti-infective Drug Development and Innovation, Victorian College of Pharmacy, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.
Li
Jian
J
Nation
Roger L
RL
D040981:Acinetobacter baumannii / Q000187:drug effects* / Q000254:growth & development; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D019540:Area Under Curve; D003091:Colistin / Q000493:pharmacokinetics / Q000494:pharmacology*; D015169:Colony Count, Microbial; D024901:Drug Resistance, Multiple, Bacterial; D007262:Infusions, Intravenous; D008826:Microbial Sensitivity Tests
D000900:Anti-Bacterial Agents; D003091:Colistin